An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

Trial Profile

An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2017 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
    • 06 Aug 2015 Planned End Date changed from 1 Dec 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 06 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top